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1. 
TREATMENT OF HEMOPHILA WITH 
HUMAN FACTOR X PRODUCED IN 
MAMIMARY TISSUE OF TRANSGENIC 
MAMMALS 
CROSS-REFERENCE TO RELATED PATENT 
APPLICATIONS 
This application is a continuation of U.S. patent applica 
tion Ser. No. 10/062,447, now abandoned, filed on Feb. 5, 
2002, which is a division of application Ser. No. 09/367,087, 
filed on Sep. 15, 1999, now Pat. No. 6,344,596, which claims 
benefit of PCT/US98/02638, filed on Feb. 13, 1998, which 
claims benefit of 60/037,145 filed on Feb. 14, 1997, all of 
which are incorporated herein by reference in their entirety. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to the production of natural 
and modified forms of Factor IX. In particular, the invention 
relates to a transgenic animal containing, stably incorporated 
in its genomic DNA, an exogenous Factor IX gene that is 
expressed specifically in mammary tissue. Such that Factor IX 
is secreted into milk produced by the animal. In particular, the 
invention relates to the production of human Factor IX in the 
milk of a transgenic non-human mammal using a DNA mol 
ecule that comprises a whey acidic protein promoter gene, 5' 
regulatory sequences containing the promoter, human Factor 
IX cDNA that lacks at least a portion of the complete or any 
portion of or the complete the 3'-untranslated region of the 
native human Factor IX gene, but contains the 5' and 3-un 
translated region of the mouse whey acidic protein gene. 
2. Background 
Human Factor IX, or “Christmas factor, is encoded by a 
single-copy gene residing on the X-chromosome at q27.1. For 
a review of Factor IX gene structure and expression, see High 
et al., “Factor IX, in MOLECULAR BASIS OF THROM 
BOSIS AND HEMOSTASIS, High (ed.), pages 215-237 (De 
kker 1995); Kurachi et al., Thromb. Haemost 73:333 (1995). 
The Factor IX gene is at least 34 kilobase (kb) pairs in size, 
and it is composed of eight exons. The major transcription 
start site of the Factor IX gene in human liver is located at 
about nucleotide-176. The human Factor IX mRNA is com 
posed of 205 bases for the 5' untranslated region, 1383 bases 
for the prepro Factor IX, a stop codon and 1392 bases for the 
3' untranslated region. 
Factor IX is synthesized as a prepropolypetide chain com 
posed of three domains: a signal peptide of 29 amino acids, a 
propeptide of 17 amino acids, which is required for Y-car 
boxylation of glutamic acid residues, and a mature Factor IX 
protein of 415 amino acid residues. The Factor IX Zymogen 
undergoes three types of post-translational modifications 
before it is secreted into the blood: a vitamin K-dependent 
conversion of glutamic acid residues to carboxyglutamic 
acids, addition of hydrocarbon chains, and B-hydroxylation 
of an aspartic acid. Mature Factor IX protein contains 12 
Y-carboxylated glutamic acid (Gla) residues. Due to the 
requirement of vitamin K by Y-carboxylase, Factor IX is one 
of several vitamin K-dependent blood coagulation factors. 
The activation of Factor IX is achieved by a two-step 
removal of the activation peptide (Ala'-Arg') from the 
molecule. Bajaj et al., “Human factor IX and factor IXa, in 
METHODS IN ENZYMOLOGY (1993). The first cleavage 
is made at the Arg-Ala'site by either Factor XIa or Factor 
VIIa?tissue factor. The second, and rate limiting cleavage is 
made at Arg'-Val. The activation pathways involving 
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Factor XIa and Factor VIIa? tissue factor are both calcium 
dependent. However, the Factor VIIa/tissue factor pathway 
requires tissue factor that is released from damaged endothe 
lial cells. Activated human Factor IX thus exists as a disulfide 
linked heterodimer of the heavy chain and light chain. Forfull 
biological activity, human Factor IX must also have the 
propeptide removed and must be fully Y-carboxylated. Kura 
chi et al., Blood Coagulation and Fibrinolysis 4:953 (1993). 
Factor IX is the precursor of a serine protease required for 
blood clotting by the intrinsic clotting pathway. Defects in 
Factor IX synthesis result in hemophilia B (or Christmas 
disease), an X-linked disorder that occurs in about one in 
30,000 males. Patients with hemophilia B are treated with 
Factor IX obtained from pooled plasma from normal indi 
viduals. Martinowitz et al., Acta Haematol 94(Suppl. 1):35 
(1995). Such Factor IX preparations, however, may be pyro 
genic and may be contaminated with pathogenic agents or 
viruses. Accordingly, it would be advantageous to develop a 
means to prepare purified Factor IX that did not require 
extraction from human plasma. 
In the past, therapeutic proteins have been produced in E. 
coli. However, limitations in secretion and post-translational 
modification which occur in all living cells has rendered 
recombinant protein production a highly species, tissue and 
cell specific phenomena. In an example of recombinant FIX 
expression in mammalian cells, the populations of recombi 
nant FIX produced in baby hamster kidney cells are not the 
same protein products as FIX produced in Chinese hamster 
ovary cells (Busby et al., Nature 316:684-686 (1985); Kauf 
man et al., J. Biol. Chem. 261: 9622-9628 (1986)). These 
proteins have profound differences in Y-carboxylation and 
propeptide removal and these differences have been estab 
lished as being very important in determining biological 
activity. Most importantly, only less than about 40 milliunits/ 
hr/ml of active rFIX were detected in CHO cells even after 
coexpression of the propeptide cleaving enzyme PACE, coex 
pression of the carboxylase enzyme, and extensive gene 
amplification with methotrexate in an attempt to increase 
expression level and activity (Wasley etal. J. Biol. Chem. 268: 
8458-84.65 (1993); Rehemtulla et al., Proc. Natl. Acad. Sci. 
(USA), 90: 4611-4615 (1993)). Researchers concluded that 
multiple limitations in the secretion of active rFIX exist in 
mammalian cells (Rehemtulla et al., 1993) and that the prob 
lem of gene transcription was secondary and indeed trivial 
with respect to post-translational processing of biologically 
active rFIX in mammaliancells. Thus, FIX mRNA splicing is 
a species specific effect occurring in mice and perhaps sheep, 
but not pigs. Although one might hypothesize that a FIX could 
be expressed, one could not predict with any certainty 
whether Such product would be a clinically acceptable, prac 
tical, recombinant therapeutic FIX product for a given hemo 
philiac indication. 
Production of recombinant Factor IX in mammalian cell 
culture (HepG2, mouse fibroblast, mouse hepatoma, rat 
hepatoma, BHK, CHO cells) repeatedly has been shown to be 
recalcitrant and cell-system specific with respect to intracel 
lular restrictions on secretion and proteolytic processing, 
post-translational modification, expression levels, biological 
activity, downstream recovery from production media, and 
substantiation of circulation half-life (Busby et al., (1985); de 
la Salle et al. Nature 316: 268-270 (1985); Anson et al., 
Nature 315: 684-686 (1985); Rehemtulla et al., 1993: Wasley, 
et al., (1993); Kaufman et al., (1986); Jallatet al., EMBO.J.9: 
3295-3301 (1990)). Importantly, the aforementioned works 
concluded that nontrivial improvements in these combined 
criteria are needed if a practical prophylactic FIX therapeutic 
product is to be made available from any recombinant mam 
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malian cell production source. For example, attempts to 
increase the specific activity of rEIX produced by CHO cells 
by rectifying problems with under-carboxylation by co-ex 
pression of the vitamin K-dependent carboxylase enzyme 
resulted in no improvement in Y-carboxylation or biological 
activity (Rehemtulla et al., (1993), implying that multiple rate 
limitations in this post-translational modification exist. 
Similar difficulties in the production of significant amounts 
of biologically active rFIX in the mammary epithelial cells of 
transgenic animals also has been documented in the literature. 
Although WO-A-90/05188 and WO-A-91-08216 predict that 
production of rEIX should be possible in their production 
systems, no data are presented in WO-A-91-08216, and only 
very low levels of secreted rEIX (25 ng/ml) with no biological 
activity were reported in transgenic sheep in WO-A90/05188 
and in related publications, (Clark et al., Bio/Technology 7: 
487-4992 (1989)). Higher expression levels have recently 
been reported in the milk of sheep (5 ug/ml), but again, the 
product had no biological activity (Colman, IBC Third Inter 
national Symposium on Exploiting Transgenic Technology 
for Commercial Development, San Diego, Calif. (1995)). 
This demonstrates that the polypeptides produced in WO-A- 
90/05188, Clark et al. (1989), and Colman (1995) were a 
different species than native human FIX with dissimilar bio 
logical activity to human FIX, and could never be used for 
therapeutic purposes. Work by Clarket al. (1992) stated that 
problems in synthesis of rPIX in the mammary gland of 
transgenic mice was the result of aberrant splicing of the rEIX 
mRNA in the 3' untranslated region. Correction of the aber 
rant splicing in transgenic mice has been demonstrated (Yull 
et al. Proc. Natl. Acad. Sci. USA 92: 10899-10903 (1995); 
Clark, et al. (1989), WO95/30000)), resulting in higher 
expression levels (up to 61 ug/ml) with about 40% biological 
active material. However, this aberrant splicing phenomenon 
appears to be species- and tissue-specific in the mouse mam 
mary gland; other reports with the 3'UTR sequences in CHO 
cell lines and in the liver of transgenic mice specifically show 
no evidence of aberrant splicing (Kaufman et al., (1986); 
Jallat et al., (1990)). In addition, no evidence was reported for 
aberrant mRNA splicing of FIX transcripts with 3' UTR 
sequences in a human hepatoma cell line (de la Salle et al., 
(1985)), amouse fibroblast cell line (de la Salleet al., (1985)), 
a rathepatoma cell line (Anson et al., 1985)), or a BHK cell 
line (Busby et al., (1985)). No data are presented to justify the 
prediction that the altered transgene of WO95/30000 will 
necessarily improve the Secretion and biological activity of 
rFIX in the milk of transgenic livestock or any other cell line. 
Therefore the claims presented in WO95/30000 are purely 
speculative and are limited to the mammary gland of trans 
genic mice. 
The stability of the rFIX product in the milk of transgenic 
livestock during upstream and downstream processing is a 
critical issue for the production of a practical therapeutic. 
Data presented in Clark et al. (1989) showed that Clark's 
method of downstream recovery of what little rFIX was in the 
milk of their transgenic sheep was not reproducible: in one of 
the preparations, a significant amount of rPIX was proteolyti 
cally activated. The infusion of activated FIX (FIXa) into a 
patient is fatal (Kingdon et al., Thrombosis, Diathes. Haem 
orrh. (Stuttg.) 33: 617 (1975)). FIX can be activated by F.XI 
and/or FVIIa/Tissue factor complex in the presence of cal 
cium and phospholipids (Kurachi et al., Blood Coagulation 
and Fibrinolysis 4: 953-974 (1993)). Milk is a medium con 
taining calcium and phospholipid surfaces. In addition, there 
is extensively conserved homology between mammalian 
blood coagulation factors, especially between porcine FXI 
and human FXI (Mashiko and Takahashi, Biol. Chem. Hoppe 
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Seyler 375: 481-484 (1994)). Detectable levels of porcine 
FVII(a) and FXI(a) in the milk of nontransgenic pigs, and 
elevated levels of FVII(a) and FXI(a) in the milk of a pig with 
mastitic milk have been measured. Thus, one could predict 
that the recovery of a useful unactivated rFIX produced in the 
milk of transgenic livestock will be very sensitive to the 
health of the mammary gland (i.e., no subclinical or clinical 
mastitis), to the milking procedure (i.e., no tissue damage), to 
pretreatment of the milk immediately after collection, to stor 
age of the milk before processing, and to the purification and 
formulation process itself. One would also predict that the 
undesirable in vivo activation of rPIX also can be minimized 
by the coexpression of inhibitors to FVIIa/TF such as the 
Tissue Factor Pathway Inhibitor (TFPI) protein, also called 
LACI, or the hybrid protein FX-LACI which is also a known 
inhibitor to FVIIa/TF. Although specific inhibitors of FXIa 
have not been identified, a similar approach can be made for 
neutralizing FXIa activation by coexpression of analogues of 
polypeptide substrates of FXIa similar to those that are com 
mercially available for amidolytic assays. Yet another strat 
egy may be to overexpress rFIX at very high levels (> 1 g/1 
milk) such that the FIX activating enzyme is extremely lim 
iting. Otherwise, steps must be taken immediately after milk 
collection to minimize activation. These include, but are not 
limited to, chelation of calcium (e.g., addition of EDTA), 
phospholipid removal, adjustment of pH, storage in ultra-low 
freezers, controlled thawing procedures, addition of protease 
inhibitors, and purification procedures that maintain minimal 
activation conduciveness. If activated rEIX still persists in the 
purified product, removal can be facilitated by lectin chroma 
tography(N-linked carbohydrate moieties exist only in the 
activation peptide), immunoaffinity chromatography using a 
Mab directed to the activation peptide, or by metal ion 
induced precipitation techniques that can select for the dif 
ferences in molecular stability of unactivated vs. activated 
FIX. Because of these inherent difficulties in production of 
active FIX at sufficiently high levels in mammalian cells and 
transgenic livestock, gene therapy has been cited as perhaps a 
more practical way of achieving a prophylactic therapeutic 
rather than recombinant technology (Kurachi et al., (1993); 
Kay et al., Proc. Natl. Acad. Sci. USA 91: 2353-2357 (1994)); 
Fallaux et al., Thromb-Haemost. 74: 266-73 (1995)). This is 
certainly a profound reality because it specifically teaches a 
product suitable for FIX prophylaxis has not yet been found 
using recombinant production in mammalian cells, even 
those that have been shown to express active FIX, albeitat low 
levels. The best recombinant FIX cell production system 
made from CHO cells is produced at low secretion levels 
(Rehemtulla et al., (1993)) and is in fact not suitable for 
prophylaxis. Furthermore, the data have shown that the 
homologous plasma proteins. FIX and protein Call have very 
different, cell-specific restrictions on post-translational pro 
cessing, proteolytic processing, and secretion which preclude 
on a protein-specific basis the predictability of high expres 
sion levels, biological activity, downstream recovery from 
production media, and predictable circulation half-life (Grin 
nell et al., “Native and Modified recombinant human protein 
C: function, secretion, and postranslational modifications. In 
Protein C and Related Anticoagulants, eds. D. F. Bruley and 
Drohan 29-63, Gulf Publishing Co., Houston, Tex. (1990); 
Yan et al., Trends in Biochem. Sci. (1989); Busby et al., 
(1985)). 
Therefore, a need still exists for a means to obtain signifi 
cant amounts of purified Factor IX from a source other than 
human plasma. A need also exists for a practical means for 
producing in mammalian cells rPIX, which is Suitable as a 
treatment for hemophilia B. 
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SUMMARY OF THE INVENTION 
Accordingly, it is an object of the present invention to 
provide a method for producing a transgenic animal that 
secretes biologically human active Factor IX into its milk. 
It is a further object of this invention to provide a transgenic 
animal that produces at least 100 ug of human Factor IX per 
milliliter of milk. 
These and other objects are achieved, in accordance with 
one embodiment of the present invention by the provision of 
a transgenic non-human mammal containing an exogenous 
DNA molecule stably integrated in its genome. 
A non-human transgenic mammal containing an exog 
enous DNA molecule stably integrated in its genome, 
wherein said exogenous DNA molecule comprises: 
(a) 5' regulatory sequences of a mammary gland-specific 
gene including a promoter; 
(b) a Factor IX-encoding DNA sequence that encodes a 
signal sequence, a Factor IX pro-sequence and a Factor 
IX sequence in a 5' to 3" direction, wherein said signal 
sequence is effective in directing the secretion of said 
Factor IX into the milk of said transgenic mammal and 
wherein said Factor IX sequence lacks at least a portion 
of the complete or the complete 5'-untranslated and 
3'-untranslated regions of the Factor IX gene.; and 
(c) 3' regulatory sequences from a mammary gland-spe 
cific gene or 3' regulatory sequences active in a mam 
mary gland; 
wherein said 5' and said 3' regulatory sequences are opera 
tively linked to said Factor IX-encoding DNA sequence. 
Mammary gland-specific promoters that are useful in the 
present invention are selected from the group consisting of 
short whey acidic protein (WAP) promoter, long WAP pro 
moter, short C.-casein promoter, short B-casein promoter, 
short kappa-casein promoter, long C-casein promoter, long 
B-casein promoter, long kappa-asein promoter, C.-lactalbu 
min promoter and B-lactoglobulin promoter. 
Non-human transgenic mammals which are contemplated 
by the present invention are selected from the group consist 
ing of mice, rats, rabbits, pigs, sheep, goats and cows. 
It is a further object to provide a process for producing 
Factor IX by providing a non-human transgenic mammal 
having integrated into its genome an exogenous DNA mol 
ecule, wherein said exogenous DNA molecule comprises: 
(a) providing a non-human transgenic mammal having 
integrated into its genome an exogenous DNA molecule, 
wherein said exogenous DNA molecule comprises: (1) 
5' regulatory sequences of a mammary gland-specific 
gene including a promoter; (2) a Factor IX-encoding 
DNA sequence that encodes a signal sequence, a Factor 
IX pro-sequence and a Factor IX sequence in a 5' to 3' 
direction, wherein said signal sequence is effective in 
directing the secretion of said Factor IX into the milk of 
said transgenic mammal and wherein said Factor IX 
sequence lacks at least a portion of the complete or the 
complete 5'-untranslated and 3'-untranslated regions of 
the Factor IX gene.; and (3)3'regulatory sequences from 
a mammary gland-specific gene or 3' regulatory 
sequences active in a mammary gland; wherein said 5' 
and said 3' regulatory sequences are operatively linked 
to said Factor IX-encoding DNA sequence; 
(b) allowing said DNA sequences encoding said Factor IX 
to be expressed and said Factor IX to be secreted into the 
milk of said transgenic mammal; 
(c) collecting said milk from said mammal; and 
(d) isolating said Factor IX from said milk. 
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It is a further object to provide a method of treating hemo 
philia B using the Factor IX produced by the transgenic 
mammal, described above. Treating involves administration 
of the Factor IX of the invention and a pharmaceutically 
acceptable carrier to a hemophilia B patient. 
It is a further object of the invention to provide an in vitro 
culture of mammary gland cells that produce Factor IX. 
Another object of the invention is to provide a method of 
treating hemophilia B by implanting Such Factor IX mam 
mary gland cells into a patient. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1A-1D schematically depict the construction of a 
chimeric Factor IX construct. Specifically, FIG. 1A shows the 
construction of pWAP4. FIG. 1B shows the production of 
pUCFIX. FIG. 1C shows the introduction of human FIX 
cDNA into pWAP4. FIG. 1D shows the production of 
pUCWAPFIX. FIX cDNA was modified by PCR in order to 
introduce KpnI sites on the 3' and 5' ends. Using FIX cDNA 
as a template, PCR primers humFIX5'KpnI and 
humFIX3'KpnI, as shown in Table 1, below, were used to 
produce FIX cloNA with KpnI sites on both ends. Modified 
cDNA may be easily into a “cassette vector' for constructing 
a chimeric gene. 
FIG. 2 shows the detection of recombinant Factor IX in 
transgenic pig milk using western blot analysis. 
FIGS. 3A-3C show the production of the puCWAP6"cas 
sette vector.” Specifically, FIG. 3A shows the production of 
pUCNotI. FIG.3B shows the production of of puCWAP5 and 
the production of a fragment that contains the puCNotIvec 
tor sequence flanked by mWAP3'UTR. FIG. 3C shows the 
production of puCWAP6. 
FIG. 4 shows the production of plasmid puCWAP6FIX. 
DETAILED DESCRIPTION 
1. Overview 
As discussed above, a method for producing significant 
quantities of Factor IX in transgenic animals has been elusive. 
Yull et al., Proc. Nat'l Acad. Sci. USA 92: 10899 (1995), 
showed that correction of a cryptic RNA splice site increases 
the amount of Factor IX synthesized by transgenic animals. In 
these studies, one transgenic mouse line produced about 27 
ug of biologically active Factor IX per milliliter of milk, 
although, Factor IX levels of individual mice of the line 
varied. Yull et al. speculated that the variation was probably 
due to epigenetic instability. 
In contrast, the studies presented herein show that trans 
genic pigs can synthesize and secrete high levels (100-200 
ug/ml milk) of biologically active recombinant human Factor 
IX in milk. Based on reduced and nonreduced SDS PAGE, the 
majority of the recombinant human Factor IX population 
appears to be a single chain polypeptide having a post-trans 
lationally modified structure similar to human Factor IX. The 
recombinant human Factor IX secreted into pig milk is bio 
logically active and is able to initiate clotting in Factor IX 
deficient human plasma. This is the first reported production 
of high levels of fully active, sufficiently Y-carboxylated, 
recombinant human Factor IX in the milk of transgenic live 
stock. 
2. Methods for Producing Transgenic Animals 
Notwithstanding past failures to express recombinant 
human Factor IX with suitably high activity in several differ 
ent expression systems, the present invention provides meth 
ods for obtaining recombinant Factor IX characterized by a 
high percentage of active protein from the milk of transgenic 
US 7,419,948 B2 
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animals. As used herein, the term “animal’ denotes all mam 
malian animals except humans. It also includes an individual 
animal in all stages of development, including embryonic and 
fetal stages. A “transgenic' animal is any animal with cells 
that contain genetic information received, directly or indi 
rectly, by deliberate genetic manipulation at the subcellular 
level, such as by microinjection or infection with recombi 
nant virus. 
The genetic information to be introduced into the animal is 
preferably foreign to the species of animal to which the recipi 
ent belongs (i.e., "heterologous'), but the information may 
also be foreign only to the particular individual recipient, or 
genetic information already possessed by the recipient. In the 
last case, the introduced gene may be differently expressed 
than is the naturally occurring, or “native.” gene. 
The language 'germ cell line transgenic animal” refers to a 
transgenic animal in which foreign DNA has been incorpo 
rated into a germ line cell, therefore conferring the ability to 
transfer the information to offspring. If such offspring, in fact, 
possess some or all of that information, then they, too, are 
transgenic animals. 
The transgenic animals of this invention are other than 
human, including, but not limited to farm animals (pigs, 
goats, sheep, cows, horses, rabbits and the like), rodents (such 
as mice), and domestic pets (for example, cats and dogs). 
Livestock animals such as pigs, sheep, goats and cows, are 
particularly preferred. 
Preferably, a transgenic animal of the present invention is 
produced by introducing into single cell embryos appropriate 
polynucleotides that encode human Factor IX, or fragments 
or modified products thereof, in a manner Such that these 
polynucleotides are stably integrated into the DNA of germ 
line cells of the mature animal, and are inherited in normal 
Mendelian fashion. 
In accordance with the invention, DNA molecules can be 
introduced into embryos by a variety of means to produce 
transgenic animals. For instance, totipotent or pluripotent 
stem cells can be transformed by microinjection, calcium 
phosphate mediated precipitation, liposome fusion, retroviral 
infection or by other means. The transformed cells can then be 
introduced into embryos and incorporated therein to form 
transgenic animals. In a preferred method, developing 
embryos can be infected with retroviral vectors and trans 
genic animals can be formed from the infected embryos. In 
the most preferred method, however, the DNA molecules of 
the invention are injected into embryos, preferably at the 
single-cell stage, which are allowed to develop into mature 
transgenic animals. However, the present invention is not 
limited to this preferred method but other methods of making 
transgenic animals can be used as described, for example, in 
Transgenic Animal Generation and Use by L. M. Houdebine, 
Harwood Academic Press, 1997. Transgenic animals also can 
be generated using methods of nuclear transfer or cloning 
using embryonic or adult cell lines as described for example 
in Campbell et al., Nature 380: 64-66 (1996) and Wilmut et 
al., Nature 385: 810-813 (1997). Further a technique utilizing 
cytoplasmic injection of DNA can be used as described in 
U.S. Pat. No. 5,523,222. 
Factor IX-producing transgenic animals can be obtained 
by introducing a chimeric construct comprising Factor IX 
encoding sequences. An alternative method of producing 
transgenic animals is to introduce a Factor IX chimeric con 
struct with a second construct that may provide higher expres 
sion more frequently than that observed with the use of Factor 
IX constructs alone. As described herein, such doubly-trans 
genic, or “bigenic animals have native WAP genomic 
sequences that are injected as separate constructs to be con 
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catenated in vivo as additional flanking sequences to the 
target Factor IX cDNA construct. 
Methods for obtaining transgenic animals are well-known. 
See, for example, Hogan et al., MANIPULATING THE 
MOUSE EMBRYO, (Cold Spring Harbor Press 1986); 
Krimpenfort et al., Bio/Technology 9:88 (1991); Pallinter et 
al., Cell 41:343 (1985); Kraemeret al., GENETIC MANIPU 
LATION OF THE EARLY MAMMALIAN EMBRYO, 
(Cold Spring Harbor Laboratory Press 1985); Hammer et al., 
Nature 315:680 (1985); Wagner et al., U.S. Pat. No. 5,175, 
385; Krimpenfort et al., U.S. Pat. No. 5,175,384, Janne et al., 
Ann. Med. 24:273 (1992), Brem et al., Chim. Oggi. 11:21 
(1993), Clarket al. U.S. Pat. No. 5,476,995, hereby incorpo 
rated by reference. 
3. Construction of Chimeric Genes 
Suitable Factor IX-encoding DNA used for producing 
transgenic animals can be obtained using human liver tissue 
as a source for cloning the human Factor IX gene. The DNA 
coding for Factor IX can be fused, in proper reading frame, 
with appropriate regulatory signals, as described in greater 
detail below, to produce a chimeric construct which is then 
amplified, for example, by propagation in a bacterial vector, 
according to conventional practice. 
The amplified construct is thereafter excised from the vec 
tor and purified for use in microinjection. The purification is 
preferably accomplished by means of high performance liq 
uid chromatography (HPLC), which removes contamination 
of the bacterial vector and from polysaccharides typically 
present when other techniques, such as conventional agarose 
electroelution, are used: The preferred HPLC method entails 
Sorbing the construct onto an anion-exchange HPLC Support 
and selectively eluting the construct from the support, pref 
erably with an aqueous sodium chloride Solution, thereby to 
eliminate contamination from the vector. Elution also may be 
effected by other means, such as a pH gradient. 
Alternatively, the excised construct can be purified by 
ultracentrifugation through an aqueous Sucrose or sodium 
chloride gradient, gel electroelution followed by agarose 
treatment and ethanol precipitation, or low pressure chroma 
tography. 
Since it is preferable that the construct have the minimum 
amount of impurities, more than one cycle of HPLC or other 
purification is advantageous. In particular, the use of HPLC 
purified DNA for microinjection, as described above, allows 
for remarkably high transformation frequencies, on the order 
of 20% or more, for example, in mice and pigs. 
DNA constructs useful in the present invention provide a 
DNA sequence encoding Factor IX, preferably human Factor 
IX, operably linked to all the cis-acting signals necessary for 
mammary tissue specific expression of Factor IX, post-trans 
lational modification of Factor IX, secretion of Factor IX into 
milk, and full biological activity of Factor IX. Although the 
present invention preferably entails the use of DNA con 
structs that produce the desired or native human Factor IX per 
se, the desired protein also may be produced as a fusion 
protein containing another protein. For example, the desired 
recombinant protein of this invention may be produced as part 
of a larger recombinant protein in order to stabilize the 
desired protein or to make its purification from milkfaster and 
easier. The fusion partners then are separated chemically or 
enzymatically, and the desired protein isolated. 
Methods for obtaining human-Factor IX-encoding DNA 
molecules and nucleotide sequences of human Factor IX gene 
and cDNA are provided, for example, by Kurachi et al., Proc. 
Nat’l Acad. Sci. USA 79:6461 (1982), Choo et al., Nature 
299: 178 (1982), Anson et al., EMBO J. 3:1053 (1984), 
Brownlee et al., international publication No. WO 84/00560, 
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Yull et al., Proc. Nat'l Acad. Sci. USA 92: 10899 (1995), 
Clark, international publication No. WO95/30000, and 
Meulien, U.S. Pat. No. 5,521,070 (1996). Human Factor IX 
probes also can be obtained from the AmericanType Culture 
Collection, Rockville, Md. (e.g., ATCC Nos. 61385, 79588, 
79602, or 79610). 
Alternatively, Factor IX-encoding DNA molecules may be 
obtained by synthesizing the genes with mutually priming 
long oligonucleotides. See, for example, Ausubel et al., Supra, 
at pages 8.2.8 to 8.2.13: Wosnicket al., Gene 60:115 (1987). 
Moreover, the polymerase chain reaction can be used to Syn 
thesize DNA fragments as large as 1.8 kilobases in length. 
Bambot et al., PCR Methods and Applications 2:266 (1993). 
Suitable Factor IX-encoding DNA molecules include 
genomic or complementary DNA molecules that encode 
naturally occurring Factor IX. In a preferred embodiment, 
DNA molecules encoding human Factor IX are employed, 
including cDNA and genomic DNA molecules. However, the 
present invention discloses that a cDNA based construct as 
described herein can be successfully used for the expression 
of human Factor IX at commercially useful levels. Particu 
larly, a cDNA based construct containing 5' regulatory 
sequences of a mammary gland specific gene including a 
promoter, a Factor IX-encoding DNA sequence as described 
herein, and 3' regulatory sequences from a mammary gland 
specific gene or 3' regulatory sequences active in a mammary 
gland is preferred. Factor IX-encoding DNA molecules from 
other species may also be used. Such as the Factor IX encoded 
by rats, pigs, sheep, cows and chimpanzees. 
It also will be appreciated that the Factor IX cDNA frag 
ment described herein can be modified using recombinant 
DNA techniques to obtain functionally equivalent molecules. 
For example, 3' or 5" portions of the Factor IX gene can be 
added, or completely deleted, or a few bases at either end may 
be removed. Introns can be removed or added, or portions of 
one or more introns can be deleted. Additional nucleotide 
sequences can be inserted into them. The sequences of the 
introns can be altered. Exons can be modified in accordance 
with the discussion of modified Factor IX molecules set forth 
below. Most modified forms of the preferred Factor IX cDNA 
fragment will not be significantly changed in their ability in 
transgenic animals to engender the production of milk-born 
Factor IX. In one embodiment, the Factor IX encoding por 
tion of the gene lacks the complete 5'-untranslated and 3'-un 
translated regions of the native Factor DX gene. Thus, these 
Substantially similar fragments will be equivalent in the 
invention to the particularly disclosed Factor IX cDNA frag 
ment. 
A 5'-untranslated region that is not the 5'-untranslated 
region of the Factor IX gene can be included in the present 
DNA Factor IX constructs, particularly the 5'-untranslated 
region of the mouse WAP gene. Likewise a 3'-untranslated 
region that is not the 3'-untranslated region of the Factor IX 
gene, particularly the 3'-untranslated region of the mouse 
WAP gene. 
Further, the Factor IX-encoding DNA molecule can also 
comprise a 5'-untranslated region located 5' from the signal 
sequence DNA, and a 3'-untranslated region located 3' from 
the Factor IX coding sequence. 
Additional useful modifications of Factor IX include those 
that alter post-translational modifications, size or active site, 
or that fuse this protein orportions thereof to another protein. 
Such modifications can be introduced into the protein by 
techniques well known in this art, Such as, by Synthesizing 
modified genes by ligation of overlapping oligonucleotide or 
introducing mutations into the cloned genes by, for example, 
oligonucleotide-mediated mutagenesis. See, generally, 
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Ausubel et al. (eds.), CURRENT PROTOCOLS IN 
MOLECULAR BIOLOGY, pages 8.0.3-8.5.9 (1990); 
McPherson (ed.), DIRECTED MUTAGENESIS: A PRAC 
TICAL APPROACH, IRL Press (1991). 
The examples described herein demonstrate that a trans 
genic animal can be produced that synthesizes a Sufficiently 
Y-carboxylated, biologically active Factor IX in mammary 
tissue. Accordingly, the basic methods of the present appli 
cation can be used to obtain transgenic animals that produce 
other vitamin K-dependent blood coagulation factors, such as 
Factor II, Factor VII, Factor X, or the anticoagulation protein, 
Protein S. DNA molecules encoding these proteins can be 
obtained by standard methods. See, for example, Pollak et al., 
J. Biol. Chem. 271: 1738 (1996), which describes the charac 
terization of the Factor VII gene, which is located on chro 
mosome 13 just 2.8 kilobase pairs 5' to the Factor X gene. 
The cis-acting regulatory regions useful in the invention 
include the promoter that drives expression of the Factor IX 
gene. Promoters particularly useful in the invention are 
“active' in mammary tissue in that the promoters are more 
active in mammary tissue than in other tissues under physi 
ological conditions where milk is synthesized. Most pre 
ferred are promoters that are both specific to and efficient in 
mammary tissue. By “efficient' it is meant that the promoters 
are strong promoters in mammary tissue that can Support the 
synthesis of large amounts of protein for secretion into milk. 
Among Such promoters, highly preferred are the short and 
long whey acidic protein (WAP), short and long C, 3 and 
kappa casein, C.-lactalbumin and B-lactoglobulin (“BLG') 
promoters. 
Promoters may be selected on the basis of the protein 
compositions of milk from various species. For example, the 
WAP and BLG promoters are particularly useful with trans 
genic rodents, pigs and sheep. The rodent WAP short and long 
promoters have been used to express the rat WAP gene, the 
human tissue-type plasminogen activator gene and the CD4 
gene, while the sheep BLG promoter has been used to express 
the sheep BLG gene, the human alpha-1-antitrypsin gene and 
the human Factor IX gene. See, for example, Paleyanda et al., 
1991, above, and Clark et al., TIBTECH 5: 20 (1987). Pre 
ferred promoters include the rodent casein and WAP promot 
ers, and the casein, C.-lactalbumin and BLG promoters from 
porcine, bovine, equine and ovine (pigs, sheep, goats, cows, 
horses), rabbits, rodents and domestic pets (dogs and cats). 
The genes for these promoters have been isolated and their 
nucleotide sequences have been published. See, for example, 
Clark et al. (1987), above, and Henninghausen, Protein 
Expression and Purification 41: 3 (1990). 
A useful promoter may be isolated by carrying out conven 
tional restriction endonuclease and Subcloning steps. A 
mouse WAP promoter, isolated as a 2.6 kb EcoRI-KpnIfrag 
ment immediately 5' to the WAP signal sequence, is preferred, 
although the “long WAP promoter (the 5' 4:2 kb Sau3A 
KpnI promoter of the mouse WAP gene, or a fragment 
thereof) is also suitable for carrying out this invention. The 
publication of Paleyanda et al., Transgenic Research 3:335 
(1994), for example, provides examples of a suitable short 
mouse WAP promoter (2.5 kb mWAP promoter) and a long 
mouse WAP promoter (“4.1 kb mWAP promoter”). Pages 
336-339 of the Paleyanda publication are incorporated by 
reference. Also see, for example, Gordon et al., Bio/Technol 
ogy 5: 1183 (1987); McKnight et al., “The Whey Acidic 
Protein, in GENES, ONCOGENES, AND HORMONES: 
ADVANCES IN CELLULAR AND MOLECULAR BIOL 
OGY OF BREAST CANCER, Dickson et al. (eds.), pages 
399-412 (Kluwer Academic Publishers 1991). Additional 
regulatory sequences direct secretion of proteins into milk 
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and/or other body fluids of the transgenic animal. In this 
regard, both homologous and heterologous regulatory 
sequences are useful in the invention. Generally, regulatory 
sequences known to direct the Secretion of milk proteins. Such 
as either signal peptides from milk or the nascent target 
polypeptide, can be used, although signal sequences can also 
be used in accordance with this invention that direct the 
secretion of expressed proteins into other body fluids, par 
ticularly-blood and urine. Examples of Such sequences 
include the signal peptides of secreted coagulation factors 
including signal peptides of Factor IX, protein C, and tissue 
type plasminogen activator. 
Among the useful sequences that regulate transcription, in 
addition to the promoters discussed above, are enhancers, 
splice signals, transcription termination signals, polyadeny 
lation sites, buffering sequences, RNA processing sequences 
and other sequences which regulate the expression of trans 
genes. Particularly useful in this regard are those sequences 
that increase the efficiency of the transcription of the genes for 
Factor IX in the mammary gland or other cells of the trans 
genic animals listed above. Preferred are transcription regu 
latory sequences for proteins highly expressed in the mam 
mary gland cells. 
Preferably, the expression system or construct of this 
invention also includes a 3' untranslated region downstream 
of the DNA sequence encoding the desired recombinant pro 
tein, or the 3' untranslated region of the milk protein gene or 
the milk protein gene with its 3' untranslated region, any of 
which can be used for regulation. This region can increase 
expression of the transgene. This region apparently stabilizes 
the RNA transcript of the expression system and thus 
increases the yield of the desired protein. Among the 3' 
untranslated regions useful in this regard are sequences that 
provide a polyA signal. 
For expression of Factor IX, it is preferred that the 3' 
untranslated region is not obtained from the native human 
Factor IX gene. Suitable heterologous 3'-untranslated 
sequences can be derived, for example, from the SV40 small 
tantigen, the casein 3' untranslated region, or other 3' untrans 
lated sequences well known in this art. Preferably, the 3' 
untranslated region is derived from a milk-specific protein, 
such as the WAP protein. The stabilizing effect of this 
region's poly A transcript is important in stabilizing the 
mRNA of the expression sequence. Ribosome binding sites 
are also importantin increasing the efficiency of expression of 
Factor IX. Likewise, sequences that regulate the post-trans 
lational modification of Factor IX are useful in the invention. 
In a particularly preferred embodiment, the transgenes of 
the invention generally consist of WAP milk protein regula 
tory sequences upstream and downstream flanking the Factor 
IX cloNA?signal peptide sequences. A native 5'-WAP regula 
tory sequence ending in an accessible restriction site imme 
diately before/at the ATG codon may be ligated to the restric 
tion sites that occur at the ATG of translatable sequences with 
no linker sequences derived from the chains of human Factor 
IX. Each of the combined 5'-regulatory and Factor IX trans 
latable sequences ending in a particular restriction site may 
then be ligated to a corresponding restriction site which 
occurs at the beginning of the 3'-untranslated region of WAP 
and adjoining WAP 3'-flanking region. This construction 
motif enables native 5'-regulatory and 3'-untranslated region 
of the milk protein genes to be immediately juxtaposed with 
out intervening sequences. Particular restriction sites at the 
ends of all constructs may be selected in order to facilitate 
concatenation of constructs into a single domain within the 
animal genome. 
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Thus, in accordance with the present invention a DNA 
molecule that encodes Factor IX is operably linked to cis 
acting regulatory sequences which allow for efficient expres 
sion of Factor IX in milk. The resulting chimeric DNA is 
introduced into a mammalian embryo, where it integrates into 
the embryonic genome and becomes part of the heritable 
genetic endowment of all the cells, including the germ line 
cells, of the adult which develops from the embryo. The 
Factor IX which is expressed in the mammary tissue and 
secreted into the milk of a transgenic mammal obtained in this 
manner displays a Surprisingly high percentage of active pro 
tein, as measured by enzymatic and coagulation-inhibition 
assays which are conventionally employed to detect Factor IX 
activity, Such as ELISAS, chromogenic activity assays and 
coagulation inhibition assays. 
4. Isolation of Factor IX from the Milk of Transgenic 
Animals 
Obtaining milk from a transgenic animal according to the 
present invention is accomplished by conventional means. 
See, for example, McBurney et al., J. Lab. Clin. Med. 64:485 
(1964); Velander et al., Proc Nat'l Acad. Sci. USA 89:12003 
(1992). Factor IX, or fragments thereof, can be isolated and 
purified from milk or urine by conventional means without 
deleteriously affecting activity. A preferred method of isola 
tion from milk consists of a combination of anion exchange 
and immunochromatography, cryoprecipitations, Zinc ion 
induced precipitation of either whole milk or milk whey 
(defatted milk) proteins. See, for example, Bringe et al., J. 
Dairy Res. 56:543 (1989). 
Milk is known to contain a number of proteases that have 
the potential to degrade foreign proteins. These include an 
alkaline protease with tryptic and chymotryptic activities, a 
serine protease, a chymotrypsin-like enzyme, an aminopep 
tidase and an acid protease. Clarket al. (1987) above. It may 
be desirable, therefore, to protect newly secreted Factor IX, or 
fragments thereof, against proteolytic degradation. Such pre 
cautions include rapid processing of the milk after collection 
and addition to the milk of well known inhibitors of proteoly 
sis, such as are listed in SIGMA CHEMICAL CO. CATA 
LOG (1993 edition) at page 850. 
Thus, in one embodiment, the transgenic mammal of the 
present invention produces active human Factor IX. For 
instance, in one embodiment wherein said mammal is a pig, 
such pig secretes from about 100 to about 220 g of active 
human Factor IX per milliliter milk. In another embodiment, 
such pig secretes from abort 100 to about 185ug of active 
human Factor IX per milliliter milk, from about 100 to about 
170 ug of active human Factor IX per milliliter of milk, from 
about 135 to about 220 g of active human Factor IX per 
milliliter of milk or from about 145 to about 220 ug of active 
human Factor IX per milliliter of milk, as set forth below. 
Factor IX produced from the transgenic mammal accord 
ing to the invention has a specific activity which is at least 
about 5 to 200 percent greater than the specific activity of 
human Factor IX isolated from human plasma, as determined 
by an activated partial thromboplastin clotting time assay. In 
another embodiment, the specific activity of Factor IX pro 
duced by the transgenic mammal of the invention is at least 
about 10 to 100 percent greater, at least about 15 to 50 percent 
greater or at least about 15 to about 46 percent greater than the 
specific activity of human Factor IX isolated from human 
plasma. 
In another embodiment, the invention relates to an in vitro 
culture of mammary gland cells explanted from the trans 
genic mammal of the invention. Such cells are explanted and 
cultured in vitro, according to methods well known to the 
skilled artisan. See e.g., U.S. Pat. No. 5,580,781. In another 
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embodiment, Factor IX is isolated and purified from the in 
vitro cell culture, according to methods well known to the 
skilled artisan. 
5. Treatment Methods 
In another embodiment, the present invention relates to a 
method of treating hemophilia Busing Factor IX produced by 
the transgenic mammal of the invention. Specifically, treat 
ment includes the prevention or amelioration of the Symp 
toms of hemophilia B in hemophilia B patients. Symptoms of 
hemophilia B include excessive bleeding upon injury, spon 
taneous bleeding, especially into weight-bearing joints, soft 
tissues and mucous membranes. Repeated bleeding into joints results in hemarthroses, which causes painful crippling 
arthropathy that necessitates joint replacement. Hematomas 
in-Soft tissues may result in “pseudo” tumors composed of 
necrotic coagulated blood. Such blood can obstruct, com 
press orrupture into adjacent organs and can lead to infection. 
Bleeding into gastrointestinal tract, central nervous system, 
intracranium or airway/retroperitoneal space can lead to 
death if not detected. This, treatment according to the present 
invention includes the prevention or amelioration of bleeding 
and the related side effects found in hemophilia B patients. 
This method involves administering to a patient having hemo 
philia B symptom, a hemophilia B symptom preventing or 
ameliorating amount of Factor IX produced by the transgenic 
mammal of the present invention. Administration may be 
accomplished by any method known to the skilled artisan. For 
instance, the treatment of the above described symptoms may 
consist of intravenous replacement therapy with Factor IX 
concentrates. Treatment of major bleeding episodes may be 
by bolus injection of concentrate. However, as described 
above, tissue damage may remain even after prompt detection 
and treatment. Prophylactic treatment is recommended to 
prevent pain and debilitation. Upon injection, 50% of Factor 
IX, according to the invention, is immediately bound to vas 
cular endothelial cells and/or diffuses into the extravascular 
space. The remaining 50% has a half life in circulation of 
approximately 24 hours. These infusion kinetics result in the 
need for injections about once to twice per week to maintain 
minimal therapeutic levels in the plasma. 
Another embodiment of the invention relates to pharma 
ceutical compositions comprising the Factor IX of the present 
invention. Such pharmaceutical composition preferably is 
Factor IX produced by the above described transgenic animal 
and a pharmaceutically acceptable carrier. For instance. Such 
pharmaceutical composition may be a stable liquid formula 
tion of the Factor IX of the invention that can be administered 
by continuous infusion to provide a constant circulating level 
of the coagulation factor. 
The Factor IX produced by the transgenic animal of the 
present invention may be concentrated and sold in lyophilized 
form, according to methods well known to the skilled artisan. 
For instance, the Factor IX of the present invention which has 
been lyophilized may be reconstituted with sterile water for 
injection (WH) and delivered in a composition of 0.01 moles/ 
liter histidine, pH 7.05; 0.066 moles/liter sodium chloride: 
3% mannitol. In another embodiment, lyophilized Factor IX 
is reconstituted in sterile WFI and delivered in a composition 
that includes: 0.04 units heparin/unit FIX: 1 milligram dex 
trose/unit Factor IX. To avoid repeated invasive treatments as 
is found with the current therapies for prophylaxis, stabilities 
of at least 30 days at 37° C. and at least 365 days at 4°C. are 
preferred. The present invention provides significant stability 
over that of these preparations reconstituted. 
This skilled artisan would know of other suitable formula 
tions for the Factor IX of the present invention. See, for 
instance, AlphaNine by Therapeutic Corporation, Los Ange 
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les, Calif., and Bebulin V. H. by Immuno, Vienna, Austria. Of 
course, any formulations according to the present invention 
are highly purified and free of viruses, prions, blood-group 
antibodies, immune complexes and phospholipids. 
Dosages or amounts that prevent or ameliorate the symp 
toms of hemophilia B are necessarily dictated by the clinical 
picture and severity of the disease. Because there is so much 
variability between patients and their clinical conditions, 
monitoring of coagulation function is essential in during any 
therapy using the Factor IX of the invention. As a rule, on 
initial treatment, one unit of Factor IX per kg body weight 
gives a mean rise in Factor IX activity of about 0.5-1%, on 
continuation therapy, the mean rise is about 1-1.5% Examples 
of dosages for long term prophylaxis of symptoms of hemo 
philia B are about 18-30 IU/kg (1x weekly) or about 9-15 
IU/kg (2x weekly). Dosages also will vary depending upon 
the purpose of the treatment. For instance, where a hemo 
philia B patient has had surgery, it may be desirable to raise 
Factor IX levels in such patients by 30 to 50% following the 
week of surgery. For dental extractions, the Factor IX levels 
may need to be raised to 50% immediately prior to the sur 
gery. Mild to moderate hemorrhages may be treated with a 
single administration of the Factor IX of the invention to raise 
Factor IX levels to 20 to 30%. In the even to more serious 
hemorrhages, it may be desirable to raise Factor IX levels to 
30 to 50% and infusions may be required daily. Again, those 
of skill in the art would know how to adjust the amount and 
frequency of dosages of the Factor IX of the present invention 
depending upon the patient and the clinical setting. 
In yet another embodiment, the invention relates to a 
method of treating hemophilia Busing Factor IX-producing 
cells that are explanted from the transgenic mammal of the 
present invention. Such mammary gland cells express Factor 
IX in Vivo, thereby preventing or ameliorating the symptoms 
of hemophilia B. This method is accomplished by using 
known techniques for gene therapy. See e.g., Debs, R. Proc. 
Natl Acad. Sci. (USA) 89: 11277-11281 (1992), Legendre et 
al., Pharmaceutical Res. 9:1235-42 (1992). In one embodi 
ment, Factor IX-producing cells removed from the transgenic 
mammal according to the invention are cultured in an in vitro 
culture system prior to transplantation into a human. Such 
culture systems are well known to the skilled artisan. See e.g. 
U.S. Pat. No. 5,580,781. The cells are treated and then trans 
planted into the patient in a manner so as to avoid rejection by 
the recipient. Such methods are known to the skilled artisan. 
See, for instance, U.S. Pat. No. 5,573.934, which teaches a 
method of encapsulating biological material for use in vivo. 
Other techniques known to the skilled artisan involve placing 
the biological material in a chamber of an immunoisolation 
apparatus and for enhancing the vascular Support for the 
implanted material using immunomodulatory agents. See, 
U.S. Pat. No. 5,569,462. 
The present invention, thus generally described, will be 
understood more readily by reference to the following 
examples, which are provided by way of illustration and are 
not intended to be limiting of the present invention. 
EXAMPLE 1. 
Preparation of a Human Factor IX Expression Vector 
for Production of Transgenic Pigs 
Generally, the entire murine WAP gene including 2.5 kb of 
5' untranslated sequence and 3' untranslated regions was 
cloned by standard methods. See Campbell et al., Nucleic 
Acids Res. 12:8685 (1984). A cDNA fragment encoding 
human Factor IX was obtained and the 3' untranslated region 
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was deleted. Using standard methods, an expression vector 
was constructed that contained a mouse WAP promoter, iso 
lated as a 2.6 kb EcoRI-KpnI fragment immediately 5' to the 
WAP signal sequence, the human Factor IX cDNA sequence 
lacking a 3' untranslated region, and a 1.6 kb fragment of the 
3' untranslated region of the WAP gene. A second expression 
vector contained a 7.2 kb mouse WAP gene (EcoRI-EcoRI) 
fragment. Expression vectors were amplified by bacterial 
transformation and purified from bacterial cultures using 
standard methods. Routine recombinant DNA techniques can 
be found, for example, in Sambrook et al., MOLECULAR 
CLONING, A LABORATORY MANUAL, Vol. 1-3 (Cold 
Spring Harbor Press 1989). 
More specifically, a chimeric Factor IX construct was pre 
pared, as follows: 
1. Preparation of a Chimeric Factor IX Construct Produc 
tion of pWAP4 “Cassette Vector 
Regulatory 5' and 3’ flanking sequences of the mouse WAP 
gene were used for mammary specific expression. Specifi 
cally, a cassette vector containing a mouse WAP promoter, 
defined as a 2.6. kb EcoRI-KpnI fragment immediately 5' to 
the WAP signal sequence and a 1.5 kb fragment of the 3' 
untranslated region of the WAP gene was prepared. These 
regulatory sequences do not include coding and intragenic 
untranslated sequences (introns) of the WAP gene. 
The vector designated pWAP4 was derived from 
pWAPPC3 (C. Russell, dissertation “Improvement of 
Expression of Recombinant Human Protein C in the Milk of 
Transgenic Mammal Using a Novel Transgenic Construct.” 
Virginia Technology Institute, Blacksburg, Va. (December 
1993)) and was developed as follows: Using WAPPC3 as a 
template, PCR primers WAP3'S2 (which contains a 5'KpnI 
site and is homologous to endogenous WAP right after the 
stop signal) and WAP3'A1, as shown in Table 1, below, were 
used to produce a segment with KpnI and BamHI sites on 
either end. This segment was digested with KpnI/BamHI and 
ligated with the vector containing the fragment from 
KpnI\BamHI digested pWAPPC3. The ligation mixture was 
used to transform E. coli DH5C. cells by electroportation with 
resultant colonies grown on LB amplicillin plates. Picked 
colonies were grown up in TB ampicillin broth, plasmids 
isolated and cut with Kp41, BamHI or both and subjected to 
gel electrophoresis. Sequencing was performed using 
WAP3'A1 primer and judged as being correct. See FIG. 1A. 
Production of Modified (Kpn I) FIX cDNA 
The FIX cDNA (containing Kpn I sites located immedi 
ately before the start sequence and after the stop sequence) 
was generated as a PCR fragment. Fragment production pro 
tocol is as follows: 100 ul total volume containing 200 uM 
dNTPs, 0.5 M of each primer (humFIX5'KpnI and 
humFIX3'KpnI, as shown in Table 1), 2.5 units Pfu poly 
merase and 30 ng of plasmidtemplate (pMCDSFIX obtained 
from Prof. Darryl Stafford, Department of Biology, Univer 
sity of North Carolina, Chapel Hill, N.C., USA), reaction 
mixture was subjected to 30 cycles of denaturation at 95°C. 
for 20 sec, annealing at 50° C. for 1 min and elongation at 75° 
C. for 5 min 45 sec. After cycling, the reaction mixture was 
subjected to blunting with T4 DNA polymerase for 10 min, 
EDTA concentration brought up to 25 mM, heated to 65° C. 
for 15 min, and extracted with Phenol: Chloroform (1:1), 
precipitated with equal volumes of 95% ethanol, aspirated, 
and Suspended in H2O. 
Ligation, Transformation and Sequencing 
As is shown in FIG. 1B, the plasmid designated puCFIX 
containing the modified (Kpn I ends) FIX cDNA was pro 
duced by digestion of both puC18 and the modified cDNA 
with Kpn I (per manufacturers instructions, Stratagene, La 
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Jolla, Calif.) purification of digestion products by CHCl: 
Phenol (1:1) extraction, precipitation with equal volumes of 
95% ethanol, aspiration and Suspension in H2O. Ligation of 
plasmid and cDNA was per manufacturers instructions (Strat 
agene) using 125 ng of Kpn I digested puC18 and 125 ng of 
Kpn I digested modified cDNA. E. coli JM109 was trans 
formed by electroportation using ligation mixture and plated 
on LB amplicillin plates. Selected colonies were grown up in 
TB ampicillin broth. Plasmid preparations from these colo 
nies were analyzed by restriction enzyme digestion (Kpn I) 
and gel electrophoresis. The entire sense strand of the cDNA 
was sequenced and found to be correct as compared with 
FIXA sequences located in Genebank. 
Introduction of FIX cDNA into pWAP4 “Cassette Vec 
torto Produce pWAPFIX 
As shown in FIG. 1C, both pWAP4 and puCFIX were 
digested with Kpn I in separate reactions, Subjected to gel 
electrophoresis and the appropriate plasmid fragments 
removed from the gel and ligated. E. coli JM109 was trans 
formed by electroportation using ligation mixture and plated 
on LB amplicillin plates. Selected colonies were grown up in 
TB ampicillin broth. Plasmid preparations from these colo 
nies were analyzed by restriction enzyme digestion (Kpn I) 
then gel electrophoresis. Clones positive for the insert were 
subjected to PCR analysis using primers FIXS1 and 
WAP3A1 to determine the correct orientation of the insert. 
Production of puCWAPFIX 
As shown in FIG. 1D, the insert containing WAP promoter, 
cDNA and 3'WAP UTR was released from pWAPFIX by 
EcoR I digestion, Subjected to gel electrophoresis, removed 
from the gel and purified. This fragment was ligated with Kpn 
Idigested puC18 and the reaction mixture used to transform 
E. coli JM109 by electroportation. After electroportation, 
cells were plated on LB ampicillin plates with picked colonies 
grown in TBampicillin broth. Plasmids from picked colonies 
were purified and subjected to EcoRI enzyme digestion and 
electrophoresis. After insert confirmation, large scale purifi 
cation was undertaken, according to methods well known to 
the skilled artisan. 
2. Preparation of Factor IX-Encoding DNA for Microin jection 
Chimeric constructs containing either the 7.2 kb mouse 
WAP gene, or containing the WAP promoter, human Factor 
IX gene and 3' WAP sequence were excised from puCWAP 
FIX by EcoRI restriction digest and purified for microinjec 
tion using low melting point agarose electrophoresis. The 
DNA: agarose band was cut from the gel slab. The agarose 
band was then treated with agarase to degrade and remove 
agarose contamination. 
After digestion, the solution containing the cDNA was 
brought to 10 mM Mg2+, 20 mM EDTA and 0.1% SDS and 
then extracted with phenol/chloroform. DNA was precipi 
tated from the aqueous layer with 2.5 volumes of ethanol in 
the presence of 0.3 M sodium acetate ate -20 degrees centi 
grade overnight. After centrifugation, the pellet was washed 
with 70% ethanol, dried, and each of the constructs was 
resuspended and dissolved in Brinsters microinjection buffer 
to a concentration of 1.4 or 7 g/ml (for mice), 14 ug/ml (for 
pigs). 
According to another protocol, extracted DNA was puri 
fied by HPLC, as follows. After cleaving a chimeric gene 
from its vector, the solution was brought to 10 mM magne 
sium, 20 mM EDTA and 0.1% SDS and then extracted with 
phenol/chloroform. DNA was precipitated from the aqueous 
layer with 2.5 volumes of ethanol in the presence of 0.3 M 
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sodium acetate at -20°C. overnight. After centrifugation, the 
pellet was washed with 70% ethanol, dried, and resuspended 
in sterile distilled water. 
The digested DNA was precipitated with isopropanol and 
then dissolved in TE buffer at 0.3 g/ml. Fragments were 5 
purified by HPLC using a Waters GEN FAX PAC HPLC 
column. The column was run isocratically using a buffer 
consisting of 25 mM Tris-HCl (pH 7.5), 1 mM sodium EDTA, 
and 0.63 MNaCl. About 15ug of digested DNA was loaded 
on the column at a time. DNA samples from all of the chro- 10 
matographic runs were then pooled, reprecipitated, and run 
through the column a second time. 
DNA concentrations were determined by agarose gel elec 
trophoresis by staining with ethidium bromide and compar 
ing the fluorescent intensity of an aliquot of the DNA with the 15 
intensity of standards. Samples were then adjusted to 10 
ug/ml and stored at -20°C., prior to microinjection. 
EXAMPLE 2 
2O 
Production of Transgenic Pigs that Express the 
Human Factor IX Gene 
Pig embryos were recovered from the oviduct, and were 
placed into a 1.5 ml microfuge tube containing approximately 25 
0.5 ml embryo transfer media (Beltsville Embryo Culture 
Medium). Embryos were centrifuged for 12 minutes at 
16,000xg RCF (13.450 RPM) in a microcentrifuge (Hermle, 
model Z231). The embryos were then removed from the 
microfuge tube with a drawn and polished Pasteur pipette and 30 
placed into a 35 mm petri dish for examination. If the cyto 
plasm was still opaque with lipid such that pronuclei were not 
visible, the embryos were centrifuged again for 15 minutes. 
Embryos were then placed into a microdrop of media (ap 
proximately 100 ul) in the center of the lid of a 100 mm petri 35 
dish, and silicone oil was used to cover the microdrop and fill 
the lid to prevent media from evaporating. The petri dish lid 
containing the embryos was set onto an inverted microscope 
(Carl Zeiss) equipped with both a heated stage and Hoffman 
Modulation Contrast optics (200x final magnification). A 40 
finely drawn (Kopf Vertical Pipette Puller, model 720) and 
polished (Narishige microforge, model MF-35) micropipette 
was used to stabilize the embryos while about 1-2 picoliters of 
HPLC-purified DNA solution containing approximately 200 
500 copies of a mixture of the two chimeric constructs was 45 
delivered into the male pronucleus with another finely drawn 
micropipette. Embryos Surviving the microinjection process 
as judged by morphological observation were loaded into a 
polypropylene tube (2 mm ID) for transfer into the recipient 
pig. 50 
EXAMPLE 3 
Production of puCWAP6 “Cassette Vector” and 
Plasmid puCWAP6FIX Production of puCWAP6 55 
“Cassette Vector' 
Generally, the entire murine WAP gene was cloned by 
standard methods, as described above in Example 1, and 
regulatory 5' and 3’ flanking sequences of the mouse WAP 60 
gene were used for mammary specific expression. Specifi 
cally, a cassette vector containing a mouse WAP promoter, 
defined as a 4.1 kb NotI-KpnI fragment immediately 5' to the 
WAP signal sequence and a 1.6 kb fragment of the 3' untrans 
lated region of the WAP gene was prepared. These regulatory 65 
sequences do not include coding and intragenic untranslated 
sequences (introns) of the WAP gene. 
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The vector designated puCWAP6 was derived from 
genetic elements from the following plasmids as starting 
material: puC18, pWAP4 and p227.6, which were provided 
by the American Red Cross. The development of puCWAP6 
is as follows: The puC18 vector was cut with the enzymes 
EcoRI and HindIII to remove the multiple cloning site of the 
vector, blunted with exonuclease and ligated with NotI link 
ers. The linearized plasmid was then cut with Not and 
ligated. Ligation mixture was used to transform E. coli DH5C. 
cells on LB amplicillin plates, picked colonies were grown in 
TBampicillin broth, plasmids were isolated and cut with NotI 
then Subjected to gel electrophoresis. Plasmid was judged to 
be correct and designated as puCNotI (See FIG. 3A). The 
vector pWAP4 was cut with EcoRI and the fragment contain 
ing the WAP 52.6 kbp and 3' genetic elements were separated 
by gel electrophoresis and purified. The ends of the fragment 
were modified by blunting with exonuclease and NotI linkers 
were ligated on. The fragment was cut with NotI and ligated 
into the NotI restriction site of puCNotI then used to trans 
form E. coli DH5C. cells on ampicillin plates picked colonies 
were grown in TB amplicillin broth. Isolated plasmid was 
verified to be correct by Not digestion with the plasmid being 
designated puCWAP5. The puC WAP5 plasmid was sub jected to KpnI digestion and a partial Not digestion produc 
ing a fragment that contained the puCNot vector sequence 
flanked by the mWAP 3'UTR (See FIG. 3B). This fragment 
was ligated with the 4.1 kb 5’ WAP promoter produced from 
digestion of p227.6 with NotI, Kipni and HindIII. The ligation 
mixture was then used to transform E. coli JM109 cells that 
were grown on LB amplicillin plates picked colonies were 
grown in TBampicillin broth, plasmids isolated were cut with 
Not I, and Notl/KpnI and judged to be correct. The plasmid 
was then designated puCWAP6 (See FIG. 3C). 
Production of puCWAP6FIX 
As shown in FIG.4, the plasmid puCWAP6FIX was pro 
duced by digestion of puCWAPFIX with KpnI and isolating 
the FIX clNA by gel electrophoresis. This fragment was 
inserted into the KpnI site of puCWAP6 after Kipni digestion 
and both fragments were then Subjected to ligation. The liga 
tion mixture was then used to transform E. coli JM109 cells 
that were then plated on LB amplicillin plates. Picked colonies 
were grown in TB amplicillin broth and plasmids were iso 
lated. Isolated plasmids were digested with NsiI to verify 
orientation of the cDNA insert. Plasmids that contained the 
insert in the correct orientation were designated 
pUCWAP6FIX. After insert confirmation, large scale purifi 
cation was undertaken, according to methods well known in 
the art. DNA was prepared for microinjection as described 
above. 
EXAMPLE 4 
Production of Transgenic Mice that Express the 
Human Factor IX Gene 
Transgenic mice were produced essentially as described by 
Hogan et al., Manipulating the Mouse Embryo, Cold Spring 
Harbor Press, (1986), which is hereby incorporated by refer 
ence. That is, glass needles for micro-injection were prepared 
using a micropipet puller and microforge. Injections were 
performed using a Nikon microscope having Hoffman Modu 
lation Contrast optics, with Narashigi micromanipulators and 
a pico-injector driven by N2 (Narashigi). 
Fertilized mouse embryos were surgically removed from 
oviducts of superovulated female CD-1 mice and placed into 
M2 medium. Cumulus cells were removed from the embryos 
with hyaluronidase at 300 g/ml. The embryos were then 
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rinsed in new M2 medium, and transferred into M15 medium 
for storage at 37 degrees centigrade prior to injection. 
Stock solutions containing about 1.4 ug/ml of the above 
described DNA were prepared and microinjected into the 
pronuclei of 1 cell mouse embryos. In addition, Stock solu 
tions containing about 7 g/ml total DNA were prepared and 
microinjected into the pronuclei of mouse embryos. 
After injecting the DNA solution into the male pronucleus, 
embryos were implanted into avertin-anesthesized CD-1 
recipient females made pseudo-pregnant by mating with 
vasectomized males. About 25-30 microinjected mouse 
embryos per recipient were transferred into pseudopregnant 
females. Embryos were allowed to come to term and the 
newborn mice were analyzed for the presence of the trans 
gene by PCR using the primers FIXS1 and FIXA1 described 
in Table 1, below. 
EXAMPLE 5 
Preparation of DNA from Transgenic Animals 
DNA can be prepared from tissue of a transgenic animal of 
any species by the method exemplified below for mice. Mar 
mur., J. Mol. Biol. 3: 208 (1961), incorporated herein by 
reference. 
A 5 mm piece of mouse tail was removed from young, 
potentially transgenic mice at weaning (3 weeks) age, and 
frozen in liquid nitrogen. To the frozen tissue was added 840 
ul of Lysing Solution (8 mM EDTA-0.8% 2-mercaptoetha 
nol-80 g/ml Proteinase K-1 M sodium chlorate in 40 mM 
TRIS buffer) pH 8.0 and 120 mM. NaCl, and the mixture 
incubated at 50 degrees centigrade. The mixture was then 
extracted with 250 ul of phenol/chloroform-fisoamyl alcohol 
(25:24:1) for 10-15 seconds, then centrifuged for 10 minutes. 
The supernatant fluid (about 830 ul) was removed to a fresh 
tube, and a DNA clot produced by vortexing the solution with 
0.6 vols. ofisopropanol. The mother liquor was decanted, and 
the DNA clot rinsed twice with 80% ethanol. The DNA clot 
was isolated by 5 minutes or centrifugation, aspiration of the 
Supernatant fluid, and air drying of the clot with a stream of air 
for 10 minutes. 
The DNA clot was dissolved in 250 ul of the TE buffer (10 
mM Tris. HCl, pH 7.0-1 mM EDTA, and the solution treated 
with 10 ul of RNase (1 mg/ml RNase A and 4,0000 units/ml 
RNAse T1) for 1 hour at 37 degrees centigrade. This mixture 
was shaken with 50 ul of a 24:1 (v/v) solution of chloroform 
isoamyl alcohol for 5-10 seconds, centrifuged, and the Super 
natant fluid transferred to a fresh tube. 
The recovered Supernatant fluid above was mixed sequen 
tially with 25 ul of 3M sodium acetate and 0.5 ml of 95% 
ethanol. The Supernatant fluid above was mixed sequentially 
with 25ul of 3M sodium acetate and 0.5 ml of 95% ethanol. 
The supernatant fluid was decanted from the precipitated 
DNA, and the precipitate washed with 80% ethanol. The 
purified DNA was isolated by centrifugation, air dried, then 
dissolved in 150 ul of TE. 
Essentially the same technique was used to prepare DNA 
from pigs, and the same or similar techniques can be used to 
prepare DNA from other animals. Such DNA can be analyzed 
to determine whether transgenic animals carried recombinant 
Structures. 
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EXAMPLE 6 
Analysis of DNA Derived from Tissue 
To determine whether test animals carried the recombinant 
constructs, tissue samples were removed from transgenic ani 
mals and treated with proteinase K and SDS at 37° C. over 
night. The mixture was then incubated with DNase-free 
RNase at 37°C. for 1-2 hours. DNA was precipitated from the 
mixture with sodium acetate and ethanol at -20°C. overnight, 
collected by centrifugation, washed in 70% ethanol and dried. 
The dried DNA pellet was used directly for polymerase chain 
reaction (PCR). In some cases, the mixture was extracted 
extensively with phenol/chloroform prior to ethanol precipi 
tation. 
Oligonucleotide pairs were used to prime polymerase 
chain reactions that detected the presence of the WAP gene or 
the Factor IX gene in the transgenic animals. See Table 1, 
below. Reactions were performed using an annealing tem 
perature of 58°C., a denaturation temperature of 94°C., and 
an extension temperature of 72° C., using 100 ng of oligo 
primers and 50 ng of (genomic) template DNA per reaction, 
and cycling through the temperatures 40 times using an auto 
matic temperature cycler (M.J. Research). PCR reactions 
were analyzed by running 20% of the reaction products on 
agarose gels and identifying fragment sizes by comparison 
with marker DNA fragments. 
Two founder transgenic pigs (one male and one female) 
contained a 2.6 kb mouse WAP promoter-Factor IX cDNA 
1.6 kb WAP gene 3'-end construct that had been coinjected 
with the 7.2 kb mouse WAP gene (EcoRI-EcoRI) fragment. 
As shown in Table 2, the male, 57-7, did not transmit the 
transgene. In contrast, founder 58-1 huas produced one 
female offspring having the Factor IX cDNA transgene. 
Founder 58-1 has produced six additional offspring, three 
females and three males, from her second litter. The three 
females were not transgenic. Two of the males from the 
second litter tested positive for the Factor IX transgene. 
TABLE 1. 
Primer Sequences 
humFIX5' (SEQ ID NO: 1) 5'gcta\gg tacc\atgcagogcg 
KpnI 
humFIX3 '' (SEQ ID NO: 2) 5'gtcavgg tacc\ttaagtgagct 
KpnI 
FIXS1 (SEQ ID NO : 3) 5'ggata acat cactcaaag cac 
WAP3 "A1 (SEQ ID NO : 4) 5' tag cagoagattgaaagcattatg 
FIXA1 (SEQ ID NO: 5) 5 "gtgaactttgtagatc 
TABLE 2 
Transgenic Pigs Containing Recombinant Human Factor IX DNA 
Pig ID Construct Sex Comments 
57-7 WAPFIX Male Founder, PCR* positive for 
WAP and FIX 
S8-1 WAPFIX Female Founder, PCR positive for WAP 
and FIX 
63-1 WAPFIX Female G' from 58-1, positive for WAP 
and FIX 
63-2 WAPFIX Female G from 58-1, positive for WAP 
and FIX (dead) 
litterii10 WAP.FIX 3Female, 2 transgenic males 
to 58-1 3Male 
WAP: Whey acid protein; FIX: Factor IX: 
*Detection of human Factor IX transgene carried out by the PCR method. 
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EXAMPLE 7 
Expression of Human Factor IX in the Milk of 
Transgenic Pigs 
Daily expression levels of recombinant human Factor IX in 
the milk of transgenic pig 58-1 were determined as follows. 
Lactating sows were injected intramuscularly with 30-60 IU 
of oxytocin (Vedco Inc., St. Joseph, Mo.) to stimulate milk 
let-down. Letdown occurred two to five minutes after injec 
tion. Pigs were milked by hand during the course of this study. 
Immediately after collection the milk was diluted 1:1 with 
200 mM EDTA, pH 7.0 to solubilize the caseins and then 
frozen. Small aliquots (about one milliliter) of the milk/ 
EDTA mixture were taken and centrifuged for approximately 
30 minutes at 16000xg at 4°C. The fat layer was separated 
from the diluted whey fraction, and the diluted whey fraction 
was used for all further assays. In this study, all concentration 
values reported for milk were obtained from diluted whey 
samples that were multiplied by a factor of 1.9 to account for 
dilution with EDTA and subsequent removal of milk fat. 
Amounts of Factor IX in milk were measured by poly 
clonal ELISA. Briefly, Immulon II microtiter plates (Fisher 
Scientific, Pittsburgh) were coated overnight with 100 ul/well 
of 1:1000 rabbit anti-human Factor IX (Dako) in 0.1 M 
NaHCO, 0.1 MNaCl, pH 9.6 at 4°C. The wells were washed 
with TBS-Tween (TBST, 25 mM Tris, 50 mM NaCl, 0.2% 
Tween 20, pH 7.2), and then blocked for 30 minutes with 
TBS/0.1% BSA at room temperature. Samples and human 
Factor IX standard (a gift from the American Red Cross) in 
the TBS-BSA dilution buffer were added in triplicate to the 
wells (100 ul/well) and incubated at 37° C. for 30 minutes. 
The wells were then washed and blocked for another 10 
minutes at room temperature. Goat anti-human Factor IX 
(American Diagnostica, Greenwich, Conn.), 1:1000 in TBS 
BSA, was then incubated in the wells for 30 minutes at 37°C., 
followed by anti-goat IgG/HRP (Sigma, St. Louis). Bound 
chromophore was detected with OPD substrate (Abbott, Chi 
cago) at 490 nm using an EL308 Bio-Tek Microplate reader. 
As shown in Table 3, daily expression levels of 100-220 
ug/ml milk were maintained throughout the 10 day lactation. 
TABLE 3 
Recombinant Factor IX Levels in Milk of 
Transgenic Pig 58-1, First Lactation 
Day of Lactation rhFIX Level g/ml) 
16O 26 
145 - 20 
1OO 25 
13S 15 
22O3O 
17O 3S 
185 SO 1 
*Recombinant human Factor IX (rhFIX) levels were determined by ELISA 
on daily samples of EDTA-diluted whey. 
EXAMPLE 8 
Western Analysis of Human Factor IX Produced by 
Transgenic Pigs 
Recombinant human Factor IX also was examined using 
Western analysis. Daily samples of EDTA-diluted whey from 
58-1 were electrophoresed on 8-16% SDS gels (Novex, San 
Diego). Approximately 125 ng of recombinant human Factor 
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IX (as determined by polyclonal ELISA) and human Factor 
IX standard (American Red Cross), were loaded in each lane. 
A total of 25ug of total protein from a pool of non-transgenic 
(NTG) whey was loaded on the gels. After electrophoresis, 
proteins were transferred overnight to PVDF membranes 
(Bio Rad). The membranes were washed for 30 minutes in 
TBST, blocked with TBS/0.05% Tween 20/0.5% Casein 
(TBST-Casein). The membranes were developed with rabbit 
anti-Factor IX (Dako) (1:1000 in TBST-Casein for 45 min 
utes at 37° C.), followed by anti-rabbit IgG/HRP (Sigma) 
(1:1000 in TBST-Casein for 45 minutes at 37° C.), and the 
DAB metal enhanced staining (Pierce). Molecular weight 
markers were purchased from Bio Rad. 
Western analyses revealed the presence of three sub-popu 
lations of recombinant human Factor IX: the major popula 
tion migrated at a M, of about 60-65 kDa, which is a slightly 
lower M, than human Factor IX, and minor sub-populations 
migrated at about 40-45 kDa, and at about 25 kDa. Plasma 
human Factor IX also possessed a subpopulation at about 
45-50 kDa. 
In yet another study, whole milk from transgenic pig 58-1 
was diluted 1:1 with 200 mM EDTA, pH 7.0 to dissociate 
casein micelles. Milk was skimmed offat by centrifugation at 
4000xg for 30 min, at 2° C. 100 ugs of milk protein were 
loaded per lane of a 4%/10% SDS-PAGE gel and resolved at 
15 mA/hr for one hour and 30 mA/hr for 2 hours. Proteins 
were transferred onto nitrocellulose paper (Amersham), at 24 
V/h, 40°C. and western blotted to detect rRIX in milk, using 
an HRP-conjugated goatanti-FIXantibody (Affinity Biologi 
cals) at 0.9 ug/ml concentration. The results of this study are 
set forth in FIG. 2, wherein lanes 1-8 represent milk from day 
3, 4, 5, 6, 7, 9, 10, 11 of lactation; lane 9, purified recombinant 
FIX, 1.0 lug; and lane 10, human FIX purified from plasma, 
0.5ug. The positions of broad range molecular weight mark 
ers (BioRad) are indicated on the left. 
EXAMPLE 9 
Purification of Human Factor IX from Milk of 
Transgenic Pigs 
Recombinant human Factor IX was purified from a pool of 
the first lactation from the milk of 58-1 using ion exchange 
chromatography followed by metal-dependent immunoaffin 
ity chromatography (MAb 1H5). In these studies, all columns 
and buffers were kept at 4° C. A pool of daily EDTA-ex 
panded whey samples was diluted to OD 280 nm of 5.0 with 
TBS, pH 7.2, then loaded at 1 cm/min on DEAE FF 
Sepharose. The column was washed with TBS, pH 7.2, and 
then eluted with 0.25 M NaCl in TBS. This fraction was 
diluted 1:1 with 40mMMgCl, in TBS to a final concentration 
of 20 mM MgCl2 and loaded on a 1H5 MAb column. The 
column was washed with TBS containing 20 mM MgCl2, and 
the product was eluted with 20 mM citrate, 0.15 MNaCl, pH 
6.8. The product was dialyzed overnight against 10 mMimi 
dazole, pH 7.2. 
The yields from the anion exchange and immunoaffinity 
steps were quantitative, and no recombinant human Factor IX 
was detected in the flow-through chromatographic fractions 
by polyclonal ELISA. This two-step chromatographic proce 
dure isolated the recombinant human Factor IX to about 
80-90% purity. 
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EXAMPLE 10 
The Biological Activity of Purified Recombinant 
Human Factor IX 
The biological activity of the purified recombinant human 
Factor IX from 58-1 was measured using a one-stage acti 
vated partial thromboplastin clotting time assay (APTT) clot 
ting assay following a protocol given by the American Red 
Cross Plasma Derivatives Laboratory (Procedure for Factor 
IX Coagulation Assay, March 1992). Briefly, each well of a 
plastic Coag-a-mate tray received 90 ul of Factor IX-deficient 
plasma plus 10 ul of a Factor IX standard or sample, diluted 
with Tris/saline/BSA. The tray was then placed on an auto 
mated analyzer (APTT mode, 240 second activation). The run 
was started, which automatically performed the addition of 
100 ul of APTT reagent and 100 ul of 0.025 M CaCl. Data 
obtained using a standard Factor IX preparation were fitted to 
the equation y-ax+b where y-clotting time and X-Factor IX, 
which was then used to determine the amount of Factor IX in 
a sample. The Standards of normal plasma reference pool 
(Sigma) and human Factor IX (American Red Cross Plasma 
Derivatives Laboratory) were used in the assay. Duplicates of 
58-1 recombinant human Factor IX, human Factor IX, and 
normal plasma reference pool samples were run at each dilu 
tion. 
As shown in Table 4, the immunopurified recombinant 
human Factor IX had a specific activity of 337 U/mg, which 
is comparable to the immunopurified human Factor IX from 
SEQUENCE LISTING 
<16 Oc NUMBER OF SEO ID NOS: 5 
<210 SEQ ID NO 1 
<211 LENGTH: 2O 
&212> TYPE: DNA 
<213> ORGANISM: Homo sapiens 
<4 OO SEQUENCE: 1 
gctaggit acc atgcagcgc.g 
<21 Oc 
<211 
SEO ID NO 2 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Homo sapiens 
<4 OO SEQUENCE: 2 
gtcaggt acc ttaagtgagc t 
SEO ID NO 3 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Homo sapiens 
<4 OO SEQUENCE: 3 
ggata acatc actcaaag.ca c 
SEO ID NO 4 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Murine 
<4 OO SEQUENCE: 4 
10 
15 
25 
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plasma which had a specific activity of 230 U/mg, and the 
normal plasma reference pool activity of 250 U/mg. 
TABLE 4 
Specific Activity of Recombinant Human Factor 
IX Purified from the Milk of a Transgenic Pig 
Slope Activity Specific 
Sample Slope Ratio Equation (%) Activity 
NPRP O.O94 1.O y = 0.094x -3.7 100% 250 U/mg 
FDX O.O86 0.92 y = 0.086x - 3.6 92% 230 U/mg 
rhEIX O.127 1.35 y = 0.127x - 3.4 13.5%. 337 U/mg 
NPRP: normal plasma reference pool 
hFIX: human Factor IX standard 
rhFIX: Factor DX isolated from the transgenic pig 
Although the foregoing refers to particular preferred 
embodiments, it will be understood that the present invention 
is not so limited. It will occur to those of ordinary skill in the 
art that various modifications may be made to the disclosed 
embodiments and that such modifications are intended to be 
within the scope of the present invention, which is defined by 
the following claims. 
All publications and patent applications mentioned in this 
specification are indicative of the level of skill of those in the 
art to which the invention pertains. All publications and patent 
applications are herein incorporated by reference to the same 
extent as if each individual publication or patent application 
were specifically and individually indicated to be incorpo 
rated by reference in its entirety. 
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- Continued 
tagcagcaga ttgaaagc at tatg 
SEO ID NO 5 
LENGTH: 16 
TYPE: DNA 
ORGANISM: Homo sapiens 
<4 OO SEQUENCE: 5 
gtgaactittg tagatc 
What is claimed is: 
1. A method of treating a patient having hemophilia B 
comprising administering to said patient a hemophilia B 
symptom preventing or ameliorating amount of a biologically 
active human Factor IX produced by a transgenic pig that 
secretes the biologically active human Factor IX into its milk, 
and wherein said transgenic pig comprises stably integrated 
into its genome an exogenous DNA molecule encoding said 
biologically active human Factor IX; and a pharmaceutically 
acceptable carrier. 
2. The method of claim 1, wherein said biologically active 
human Factor IX has a specific activity that is at least about 
15-50% greater than the specific activity of human Factor IX 
isolated from human plasma. 
3. The method of claim 1, wherein said transgenic pig 
secretes at least 100 ug of biologically active human Factor IX 
per milliliter of milk. 
4. The method of claim 1, wherein said amount of said 
human Factor IX that is administered comprises about 18-30 
IU/kg administered once a week. 
5. The method of claim 1, wherein said administration of 
said human Factor IX raises Factor IX levels 20% or greater 
in the blood. 
6. A purified or isolated biologically active human Factor 
IX produced in a transgenic pig which secretes said biologi 
cally active human Factor IX into its milk, wherein said 
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transgenic pig comprises stably integrated into its genome an 
exogenous DNA molecule encoding said biologically active 
human Factor IX. 
7. The biologically active human Factor IX of claim 6, 
wherein said biologically active human Factor IX comprises 
a specific activity that is at least about 15-50% greater than the 
specific activity of human Factor IX isolated from human 
plasma. 
8. The biologically active human Factor IX of claim 6, 
wherein said transgenic pig secretes at least 100 ug of bio 
logically active human Factor IX per milliliter of milk. 
9. The biologically active human Factor IX of claim 6, 
wherein said biologically active human Factor IX comprises 
a sufficiently Y-carboxylated, biologically active Factor IX. 
10. The biologically active human Factor IX of claim 6, 
wherein said biologically active human Factor IX further 
comprises a pharmaceutically acceptable carrier. 
11. The method of claim 1, wherein said amount of said 
human Factor IX that is administered comprises about 9-15 
IU/kg administered twice a week. 
12. The method of claim 1, wherein said administration of 
said human Factor IX raises Factor IX levels to 50% in the 
blood. 
13. The method of claim 1, wherein said biologically active 
human Factor IX is isolated or purified from said milk. 
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